
NASDAQHealthcareMedical - Instruments & Supplies
أحدث البيانات المتاحة
173.88 US$
+10.04 US$ · +6.13%
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
الإغلاق السابق
173.88 US$
+10.04 US$ · +6.13%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
نطاق اليوم
السعر الحالي 173.88 US$
نطاق 52 أسبوعًا
السعر الحالي 173.88 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
16
مبالغ في سعره
المشاعر
67
صعودي
المخاطر
46
مخاطر أعلى من المعتاد
الزخم
47
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
نطاق اليوم
السعر الحالي 173.88 US$
نطاق 52 أسبوعًا
السعر الحالي 173.88 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 738.26 مليون USD | 634.44 مليون USD | 632.36 مليون USD | 801.54 مليون USD | 670.53 مليون USD |
| تكلفة البضاعة المباعة | 390.63 مليون USD | 359.79 مليون USD | 353.92 مليون USD | 345.83 مليون USD | 279.28 مليون USD |
| الربح الإجمالي | 347.62 مليون USD | 274.65 مليون USD | 278.44 مليون USD | 455.71 مليون USD | 391.25 مليون USD |
| البحث والتطوير | 54.18 مليون USD | 43.2 مليون USD | 42.72 مليون USD | 43.94 مليون USD | 34.27 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 290.51 مليون USD | 263.37 مليون USD | 218.58 مليون USD | 215.83 مليون USD | 183.87 مليون USD |
| نفقات التشغيل | 288.05 مليون USD | 309.76 مليون USD | 230.74 مليون USD | 231.04 مليون USD | 224.01 مليون USD |
| دخل الفوائد | 27.57 مليون USD | — | — | 6.98 مليون USD | 176 ألف USD |
| مصاريف الفوائد | 23.17 مليون USD | 22.57 مليون USD | 10.03 مليون USD | 2.98 مليون USD | 12.71 مليون USD |
| الاستهلاك والإطفاء | 96.96 مليون USD | 86.56 مليون USD | 86.11 مليون USD | 57.01 مليون USD | 38.45 مليون USD |
| الدخل التشغيلي | 59.58 مليون USD | −35.11 مليون USD | 47.7 مليون USD | 224.67 مليون USD | 167.25 مليون USD |
| صافي الدخل | 48.89 مليون USD | −25.51 مليون USD | 35.6 مليون USD | 185.96 مليون USD | 128.29 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI308.01 مليون0.01%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard Morningstar Small-Cap ETFVB223.15 مليون0.12%185.3 مليار USD0.03%289.48 US$+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK128.1 مليون0.28%44.7 مليار USD0.05%344.74 US$+1.22%
Vanguard Extended Market ETFVXF111.55 مليون0.11%95.4 مليار USD0.05%235 US$+0.80%
First Trust NYSE Arca Biotechnology Index FundFBT109.14 مليون3.77%2.89 مليار USD0.55%265.4 US$+2.00%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY77.22 مليون0.30%25.82 مليار USD0.23%669.87 US$+0.54%
Dimensional - US Small Cap ETFDFAS73.77 مليون0.22%33.87 مليار USD0.31%78.35 US$+0.32%
iShares Biotechnology ETFIBB67.67 مليون0.64%10.82 مليار USD0.44%206.49 US$+3.00%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
First Trust NYSE Arca Biotechnology Index FundFBT
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
Dimensional - US Small Cap ETFDFAS
iShares Biotechnology ETFIBBالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.